Key Developments: AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

66.35USD
22 May 2015
Change (% chg)

$0.17 (+0.26%)
Prev Close
$66.18
Open
$66.27
Day's High
$66.94
Day's Low
$65.37
Volume
168,305
Avg. Vol
214,387
52-wk High
$68.21
52-wk Low
$17.37

Search Stocks

Latest Key Developments (Source: Significant Developments)

AMAG Pharmaceuticals Inc raises FY 2015 guidance
Tuesday, 5 May 2015 06:00am EDT 

AMAG Pharmaceuticals Inc:Sees FY 2015 total revenue between $395 to $430.Sees FY 2015 Adjusted EBITDA between $200 to $220.  Full Article

AMAG Pharmaceuticals Inc announces closing of $201 mln public offering of common stock including full exercise of underwriters' option
Tuesday, 3 Mar 2015 05:00pm EST 

AMAG Pharmaceuticals Inc:Says closing of its previously said public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 596,590 shares of common stock at the public offering price of $44.00 per share.Says exercise of underwriters' option brought total number of shares of common stock sold by AMAG to 4,573,862 and increased the total gross proceeds raised in offering to about $201.2 mnl, before deducting underwriting discounts, commissions and estimated expenses.J.P. Morgan and Deutsche Bank Securities acted as joint book-running managers for offering.Cowen and Company and Baird acted as co-managers for offering.  Full Article

AMAG Pharmaceuticals, Inc prices public offering of $175 million of common stock
Wednesday, 25 Feb 2015 06:27pm EST 

AMAG Pharmaceuticals, Inc:Announced that it has priced its previously announced underwritten public offering of common stock consisting of 3,977,272 shares at a public offering price of $44.00 per share.Gross proceeds to AMAG from this offering are expected to be about $175 million.AMAG intends to use the net proceeds from this offering for general corporate purposes, including to continue the expansion and diversification of its product portfolio through the in-license or purchase of additional pharmaceutical products or companies.AMAG has granted the underwriters a 30-day option to purchase up to an additional 596,590 shares of common stock offered in the public offering.All of the shares in the offering will be sold by AMAG.The offering is expected to close on March 3, 2015.J.P. Morgan and Deutsche Bank Securities are acting as joint book-running managers for the offering.Cowen and company and Baird are acting as co-managers for the offering.  Full Article

AMAG Pharmaceuticals Inc proposes public offering of $125 mln of common stock
Tuesday, 24 Feb 2015 04:05pm EST 

AMAG Pharmaceuticals Inc:Commences underwritten public offering of about $125 mln of shares of its common stock.Intends to grant the underwriters a 30-day option to purchase up to an additional 15 pct of the shares of the common stock offered in the public offering.All of the shares in the offering will be sold by AMAG.J.P. Morgan and Deutsche Bank Securities are acting as joint book-running managers for the offering.Offering is subject to market and other conditions and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Intends to use the net proceeds for general corporate purposes, including to continue the expansion and diversification of its product portfolio through the in-license or purchase of additional pharmaceutical products or companies.  Full Article

AMAG Pharmaceuticals Inc gives FY 2015 earnings guidance in line with analysts' estimates-Conference Call
Monday, 9 Feb 2015 04:30pm EST 

AMAG Pharmaceuticals Inc:Expects FY 2015 non-GAAP adjusted EBITDA range of between $180 and $200 million.FY 2015 non-GAAP cash earnings of between $150 and $170 million.FY 2015 EBITDA of $192 million - Thomson Reuters I/B/E/S.  Full Article

AMAG Pharmaceuticals Inc gives Q4 2014 and FY 2014, 2015 revenue guidance above analysts' estimates
Sunday, 11 Jan 2015 05:00pm EST 

AMAG Pharmaceuticals Inc:Sees Q4 2014 total revenues of between $52.8 million and $54.5 million.Sees FY 2014 total revenues of between $123.8 million and $125.5 million.Sees FY 2015 total revenue of between $380 million and $420 million.Q4 2014 revenue of $37.8 million - Thomson Reuters I/B/E/S.FY 2014 revenue of $108.8 million - Thomson Reuters I/B/E/S.FY 2015 revenue of $365 million - Thomson Reuters I/B/E/S.  Full Article

AMAG Pharmaceuticals completes acquisition of Lumara Health's Maternal Health Business
Wednesday, 12 Nov 2014 04:00pm EST 

AMAG Pharmaceuticals Inc:Completed the acquisition of Lumara Health Inc., a specialty pharmaceutical company with a particular focus on maternal health.Says the transaction was announced on Sept. 29, 2014 and included upfront consideration of $600 million in cash and 3,209,971 shares of AMAG common stock, and additional contingent consideration of up to $350 million based on the achievement of sales milestones.  Full Article

AMAG Pharmaceuticals to acquire Lumara Health Maternal Health Business; gives FY 2015 guidance
Monday, 29 Sep 2014 06:55am EDT 

AMAG Pharmaceuticals Inc:To acquire Lumara Health Inc., a privately-held pharmaceutical company specializing in women's health, for $675 mln ($600 mln in cash and $75 mln in stock) and additional contingent consideration of up to $350 mln based on achievement of certain sales milestones.Transaction is expected to result in projected combined FY 2015 product sales of $350 mln and is expected to be immediately accretive to adjusted earnings per share, with cost synergies of at least $20 mln per year.  Full Article

AMAG Pharmaceuticals Inc raises FY 2014 revenue guidance; lowers FY 2014 net income guidance
Tuesday, 29 Jul 2014 07:00am EDT 

AMAG Pharmaceuticals Inc:Increases FY 2014 total revenue guidance of between $93 mln and $102 mln, including U.S. Feraheme net product sales of $80 mln to $87 mln, revised upward from the company's previous estimate of $75 mln to $85 mln.Increases FY 2014 net loss guidance to $12 mln to $14 mln from the company's previous estimate of $10 mln to $12 mln.FY 2014 revenue of $94 mln and net income of $(0.6) mln - Thomson Reuters I/B/E/S.  Full Article

AMAG Pharmaceuticals Inc announces publication of data from a multi-institutional trial of MuGard
Monday, 28 Apr 2014 08:00am EDT 

AMAG Pharmaceuticals Inc:Says the publication of data from a multi-institutional trial of MuGard has been featured in the print edition of the journal Cancer, available on April 28.MuGard is a mucoadhesive hydrogel that forms a protective coating over the oral mucosa.Randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing the mouth and throat soreness associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.No difference in adverse effects was observed between patients receiving MuGard and those patients receiving the saline-bicarbonate control.No patients discontinued MuGard because of an adverse effect while two patients using the sham-control discontinued due to nausea or vomiting.  Full Article

Search Stocks